Awakn Life Sciences Corp (TSE:AWKN) has released an update.
Awakn Life Sciences Corp. has initiated a Licensing Partnership with Rivus Wellness and Research Institute in Oklahoma City, marking its first venture into the U.S. southern states, aiming to offer its proven Awakn Kare treatment for Alcohol Use Disorder, which boasts an 86% abstinence rate post-treatment. In addition to the licensing news, Awakn successfully closed the fourth tranche of a non-brokered private placement, raising a total of $2,964,663. This partnership and funding effort highlight Awakn’s commitment to advancing effective addiction treatments and expanding its market presence.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
